Skip to main content
ScholarsBetaWeill Cornell Medicine

Overview

Pilot Study for the Safe Use of Secretin on Autistic Children, 1998-2000

Publications

25 publications

Funding

1 grant
Completed grants (1)
  • PI
    Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children with Crohn's Disease: A Retrospective Cohort Study using the ImproveCareNow Registry Data
    ImproveCareNow Inc. · 2022–2022Contract
    ICN SRA 222376

Clinical research

6 studies

Active

3 studies
  • PI
    Clinical Outcomes of Medications Post Anti-TNF: Researching Effectiveness in Pediatric IBD
    University of North Carolina at Chapel Hill · OPEN TO ACCRUAL (as of 2026)
    Ulcerative Colitis, Pediatric; Inflammatory Bowel Diseases; Crohn Disease
    NCT07198113
  • PI
    Precision Medicine in Pediatric Inflammatory Bowel Disease Care
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)
  • PI
    Developing and validating a predictive model for the treatment of iron deficiency anemia in pediatric Crohnâ s disease through analysis of microbiome and patient laboratory data
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2023)
Completed & closed trials (3)
  • PI
    OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    PHASE3 · Pfizer, Inc. · IRB STUDY CLOSURE (as of 2025)
    Ulcerative Colitis
    NCT04624230
  • PI
    Real-world Evidence for the Effectiveness and Safety of Ustekinumab Treatment in Children with Crohn's Disease: A Retrospective Cohort Study using the ImproveCareNow Registry Data
    Cincinnati Children’s Hospital Medical Center · IRB STUDY CLOSURE (as of 2023)
  • PI
    Prometheus - 18IBD01 - Biomarkers Detection in Crohn's Disease
    Prometheus Laboratories, Inc. · IRB STUDY CLOSURE (as of 2022)

News mentions

5 mentionsView all WCM news ↗
  • Putting the Brakes on Chronic Inflammation
    June 12, 2024

    Scientists at Weill Cornell Medicine discovered a previously unknown link between two key pathways that regulate the immune system in mammals—a finding that impacts our understanding of chronic inflammatory bowel diseases (IBD).

  • Discovery Reveals How the Immune System Tolerates Friendly Gut Bacteria
    September 7, 2022

    Immune cells called group 3 innate lymphoid cells (ILC3s) play an essential role in establishing tolerance to symbiotic microbes that dwell in the human gastrointestinal tract, according to a study led by researchers at Weill Cornell Medicine.

  • Scientists Identify a Key Molecular Protector of Gut Health
    July 13, 2022

    A protein called Zbtb46, expressed by specialized immune cells, has a major role in protecting the gastrointestinal tract from excessive inflammation, according to a study from researchers at Weill Cornell Medicine.

  • Immune Cells Heal the Intestine by Controlling Iron
    April 14, 2020

    An iron-regulating molecule called hepcidin is produced by the immune system and restricts the growth of gut bacteria after an intestinal injury, helping to heal the lining of the intestine, according to a study by Weill Cornell Medicine, NewYork-Presbyterian and Institut Cochin investigators.

  • Researchers Discover New Pathway Regulating Intestinal Health that is Impaired in Children with IBD
    April 3, 2019

    Production of an essential protein for maintaining a healthy immune response in the intestine called interleukin-2 (IL-2) depends on immune cells known as innate lymphoid cells (ILCs), according to a study by Weill Cornell Medicine researchers.